3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Glioblastoma
7
Squamous Cell Carcinoma of Head and Neck
2
Esophageal Squamous Cell Carcinoma
2
Carcinoma, Non-Small-Cell Lung
2
Brain Neoplasms
2
Astrocytoma
2
Wilms Tumor
1
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Recurrence
1
Neuroblastoma
1
Neoplasms
1
Meningioma
1
Melanoma
1
Hepatoblastoma
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Squamous Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Merkel Cell
1
Interventions
Magnetic Resonance Spectroscopy
16
Hydroxyurea
7
Everolimus
7
Bevacizumab
7
lutetium Lu 177 dotatate
6
gallium Ga 68 dotatate
6
Radiosurgery
6
Proton Therapy
6
Specimen Handling
5
pembrolizumab
4
Surveys and Questionnaires
4
Surgical Procedures, Operative
4
Radiotherapy
4
Imatinib Mesylate
4
Cyclophosphamide
4
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
4
aldesleukin
3
abemaciclib
3
Tranexamic Acid
3
Temozolomide
3
Sunitinib
3
Sodium Chloride
3
Radiotherapy, Intensity-Modulated
3
Observation
3
Nivolumab
3
Ga(III)-DOTATOC
3
90Y-octreotide, DOTA-Tyr(3)-
3
vistusertib
2
trametinib
2
ribociclib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Meningioma
×
regorafenib
×
CNS
×
Clear all
NCT06275919
2026-05-13
MIRAGE
Istituto Oncologico Veneto IRCCS
Phase 2
Recruiting
104 enrolled